New project aims to increase the EU’s ability to combat flavivirus threats

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

Anap­tys­Bio’s an­ti­body for a rare form of pso­ri­a­sis passed a Phase III study, but it’s still get­ting the boot, the com­pa­ny an­nounced on Mon­day. Af­ter